Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
Follow-Up Questions
Bristol-Myers Squibb Co의 CEO는 누구입니까?
Dr. Christopher Boerner은 2018부터 회사에 합류한 Bristol-Myers Squibb Co의 Chairman of the Board입니다.
BMY 주식의 가격 성능은 어떻습니까?
BMY의 현재 가격은 $45.26이며, 전 거래일에 decreased 0.77% 하였습니다.
Bristol-Myers Squibb Co의 주요 사업 주제나 업종은 무엇입니까?
Bristol-Myers Squibb Co은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Bristol-Myers Squibb Co의 시가총액은 얼마입니까?
Bristol-Myers Squibb Co의 현재 시가총액은 $92.1B입니다
Bristol-Myers Squibb Co는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 26명의 분석가가 Bristol-Myers Squibb Co에 대한 분석 평가를 실시했으며, 이는 4명의 강력한 매수, 6명의 매수, 21명의 보유, 2명의 매도, 그리고 4명의 강력한 매도를 포함합니다
